<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Polachova E</submitter><funding>Akademie Ved Cesk? Republiky</funding><funding>Deutsche Forschungsgemeinschaft</funding><funding>Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy</funding><funding>European Regional Development Fund</funding><pagination>251-265</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9841525</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>66(1)</volume><pubmed_abstract>The mitochondrial rhomboid protease PARL regulates mitophagy by balancing intramembrane proteolysis of PINK1 and PGAM5. It has been implicated in the pathogenesis of Parkinson's disease, but its investigation as a possible therapeutic target is challenging in this context because genetic deficiency of PARL may result in compensatory mechanisms. To address this problem, we undertook a hitherto unavailable chemical biology strategy. We developed potent PARL-targeting ketoamide inhibitors and investigated the effects of acute PARL suppression on the processing status of PINK1 intermediates and on Parkin activation. This approach revealed that PARL inhibition leads to a robust activation of the PINK1/Parkin pathway without major secondary effects on mitochondrial properties, which demonstrates</pubmed_abstract><journal>Journal of medicinal chemistry</journal><pubmed_title>Chemical Blockage of the Mitochondrial Rhomboid Protease PARL by Novel Ketoamide Inhibitors Reveals Its Role in PINK1/Parkin-Dependent Mitophagy.</pubmed_title><pmcid>PMC9841525</pmcid><funding_grant_id>Le2749/1-2 263531414/FOR2290</funding_grant_id><funding_grant_id>LO1302</funding_grant_id><funding_grant_id>RVO 61388963</funding_grant_id><funding_grant_id>CZ.02.1.01/0.0/0.0/16_019/0000729</funding_grant_id><pubmed_authors>Polachova E</pubmed_authors><pubmed_authors>Ticha A</pubmed_authors><pubmed_authors>Strisovsky K</pubmed_authors><pubmed_authors>Majer P</pubmed_authors><pubmed_authors>Heuten E</pubmed_authors><pubmed_authors>Lampe P</pubmed_authors><pubmed_authors>Bach K</pubmed_authors><pubmed_authors>Langer T</pubmed_authors><pubmed_authors>Stanchev S</pubmed_authors><pubmed_authors>Lemberg MK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Chemical Blockage of the Mitochondrial Rhomboid Protease PARL by Novel Ketoamide Inhibitors Reveals Its Role in PINK1/Parkin-Dependent Mitophagy.</name><description>The mitochondrial rhomboid protease PARL regulates mitophagy by balancing intramembrane proteolysis of PINK1 and PGAM5. It has been implicated in the pathogenesis of Parkinson's disease, but its investigation as a possible therapeutic target is challenging in this context because genetic deficiency of PARL may result in compensatory mechanisms. To address this problem, we undertook a hitherto unavailable chemical biology strategy. We developed potent PARL-targeting ketoamide inhibitors and investigated the effects of acute PARL suppression on the processing status of PINK1 intermediates and on Parkin activation. This approach revealed that PARL inhibition leads to a robust activation of the PINK1/Parkin pathway without major secondary effects on mitochondrial properties, which demonstrates</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-07-14T17:05:52.037Z</modification><creation>2025-04-06T13:12:31.369Z</creation></dates><accession>S-EPMC9841525</accession><cross_references><pubmed>36540942</pubmed><doi>10.1021/acs.jmedchem.2c01092</doi></cross_references></HashMap>